By the pharmacological inhibition of cholinesterases (the enzymes responsible for acetylcholine catabolism), acetylcholine levels in patients with AD are increased, thereby counteracting the deficit in cholinergic transmission (11). This evidence concerns the gene BCHE and Alzheimer disease.